The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksManolete Partn. Regulatory News (MANO)

Share Price Information for Manolete Partn. (MANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 142.50
Bid: 140.00
Ask: 145.00
Change: 2.50 (1.79%)
Spread: 5.00 (3.571%)
Open: 142.50
High: 142.50
Low: 142.50
Prev. Close: 140.00
MANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

H1 Trading Update

9 Sep 2022 07:00

RNS Number : 8547Y
Manolete Partners PLC
09 September 2022
 

9 September 2022

THE INFORMATION COMMUNICATED IN THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014 ("MAR"). Steven Cooklin Chief Executive Officer of Manolete Partners Plc is the person responsible for this disclosure.

Manolete Partners Plc

("Manolete" or the "Company")

H1 Trading Update

Manolete Partners Plc (AIM: MANO), the leading listed insolvency litigation financing firm in the UK, announces that it has received a rare adverse decision in the High Court on one of its larger cases. While Manolete has applied for permission to appeal this surprising decision, the Board has decided to write down the full value of the case in its forthcoming results for the six months ended 30 September 2022 ("FY23 Interim Results"). The impact will be a reduction of £2.3m to pre-tax profits, of which the cash costs paid out on this case to date are £636,756.

Separately, reflecting the widely reported deterioration and challenges presenting in the UK macro-economic climate, the Board has taken a more prudent view of the valuation of the Company's c.280 ongoing litigation case investments.

As a combination of both of these factors, the Company expects to announce a pre-tax loss of c.£5m in the FY23 Interim Results, the large majority of which will be due to the adjustment of unrealised revenues and unrealised profits.

Underlying business performance and cash generation

Despite these negative factors, the business continues to operate well, in particular, gross cash generation from completed cases in the first five months of the current trading year is at a record £15m. This compares to £15.6m gross cash generation for the entire 12 months for the year ended 31 March 2022. This strong cash performance enabled the Company to repay a net £3.7m of indebtedness during the first half of this financial year. Furthermore, unaudited realised revenues, on completed cases, for the first five months of FY23 were 175% higher at £10.6m (FY22: £3.9m).

From 1 April 2022, UK insolvency regulations returned to normal after a near two-year suppression of insolvencies by the Government in response to the Covid-19 pandemic. The benefits of this are now starting to flow into the Company's key performance metrics, with new case enquiries already up 24% compared to the whole of H1 FY22. The Company is also working closely with blue-chip strategic financial services and Government entities, which may lead to a material involvement in the recovery of monies loaned to UK SMEs under the Bounce Back Loan schemes. The Company will provide a further update when the FY23 Interim Results are published.

Steven Cooklin, CEO of Manolete commented: "The Board and our legal advisers were surprised and disappointed by the very rare adverse initial judgment that we received on one of our larger cases, a case that we originally signed up in 2019. For the first time in our 13-year history, we have applied for permission to appeal that decision to the Court of Appeal. We have taken a cautious stance by reducing the carrying value of that case to zero until we know the final outcome of the appeal process. On the wider front, while we have taken a deliberately prudent view on the latest valuation of the portfolio of our 280 in-process cases, we note that our key forward-looking performance indicator of 'new case enquiries' is now showing strong signs of recovery. I am optimistic that the second half of this financial year and beyond will see much improved trading results".

 

For further information, please contact:

Manolete Partners Plc via Instinctif Partners

Steven Cooklin (Chief Executive Officer)

Peel Hunt (NOMAD and Sole Broker) +44 (0)20 7418 8900

Paul Shackleton

Instinctif Partners (Financial PR)

Tim Linacre +44 (0)7949 939237

Victoria Hayns

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFFELARITIIF
Date   Source Headline
18th Apr 20247:00 amRNSTrading and Business Update
26th Feb 20247:00 amRNSAppointment of Nominated Adviser and Broker
1st Dec 20237:00 amRNSBlock Listing Six Monthly Return
16th Nov 20237:00 amRNSHalf Year Results
9th Nov 20231:50 pmRNSNOTICE OF HY RESULTS, RETAIL INVESTOR PRESENTATION
25th Oct 20239:32 amRNSPresenting at Proactive One2One Investor Forum
18th Oct 20237:00 amRNSTrading Update
19th Sep 20235:15 pmRNSResult of AGM
1st Aug 202311:33 amRNSUpdate regarding the PACCAR Matter
1st Aug 20237:00 amRNSGrant of Share Options
20th Jul 20237:00 amRNSGrant of Share Options
7th Jul 20237:00 amRNSDirector/PDMR Shareholding
5th Jul 20234:57 pmRNSPosting of Annual Report and Notice of AGM
29th Jun 20237:00 amRNSThird Year: Band 1 Insolvency Litigation Funding
22nd Jun 20237:00 amRNSAudited results for the year ended 31 March 2023
13th Jun 202310:30 amRNSInvestor Presentation via Investor Meet Company
13th Jun 20237:00 amRNSNotice of Results
1st Jun 20237:00 amRNSBlock Listing Six Monthly Return
22nd May 20237:00 amRNSRetail Investor Presentation at Mello2023
20th Apr 202312:30 pmRNSCORRECTION Further Trading Update
20th Apr 20237:00 amRNSFurther Trading Update
14th Mar 20231:49 pmRNSTrading Update
6th Feb 20237:00 amRNSHire of Former Government Counter-Fraud Expert
21st Dec 20229:11 amRNSDirector/PDMR Shareholding
1st Dec 20227:00 amRNSBlock listing Six Monthly Return
10th Nov 20227:00 amRNSHalf Year Results
3rd Nov 20227:00 amRNSNotice of HY Results, Retail Investor Presentation
23rd Sep 20222:37 pmRNSUpdate on case
20th Sep 20222:00 pmRNSResult of AGM
9th Sep 20227:00 amRNSH1 Trading Update
1st Aug 202210:29 amRNSTotal Voting Rights
1st Aug 20227:00 amRNSGrant of Share Options and deferred bonus award
5th Jul 20225:04 pmRNSNotice of AGM
1st Jul 20227:00 amRNSBand 1 Ranking for Insolvency Litigation Funding
23rd Jun 20227:01 amRNSDirectorate Change
23rd Jun 20227:00 amRNSAudited results for the year ended 31 March 2022
16th Jun 20227:00 amRNSRetail Investor Presentation
15th Jun 20227:00 amRNSNotice of Results
1st Jun 20227:00 amRNSBlock Listing Six Monthly Return
3rd May 20227:00 amRNSTotal Voting Rights
26th Apr 20227:00 amRNSUpdate to recent Trading Statement & cash receipt
11th Apr 20227:00 amRNSTrading and business update
1st Mar 20227:00 amRNSTotal Voting Rights
6th Jan 20227:00 amRNSAppointment of Independent Non-Executive Director
4th Jan 20223:34 pmRNSTotal Voting Rights
3rd Dec 20217:00 amRNSGrant of Share Options
1st Dec 20217:00 amRNSTotal Voting Rights
30th Nov 202111:03 amRNSDirector/PDMR Dealings
26th Nov 202112:52 pmRNSBlock Listing Application
11th Nov 20217:00 amRNSHalf Year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.